Buy 1cP-MiPLA for sale online - USA vendor

Table of Contents

1. Introduction
   
   
• 1.1 Overview of 1cP-MiPLA
• 1.2 Emergence and Synthesis
2. Pharmacology
   
   
• 2.1 Mechanism of Action
• 2.2 Prodrug Potential
• 2.3 Comparison with LSD
• 2.4 Dosage Information
• 2.5 Subjective Effects
• 2.5.1 Disclaimer
3. Physical Effects
   
   
• 3.1 Stimulation
• 3.2 Spontaneous Bodily Sensations
• 3.3 Physical Euphoria
• 3.4 Changes in Felt Bodily Form
• 3.5 Tactile Enhancement
• 3.6 Other Physical Effects
4. Visual Effects
   
   
• 4.1 Enhancements
• 4.1.1 Visual Acuity Enhancement
• 4.1.2 Colour Enhancement
• 4.1.3 Pattern Recognition Enhancement
• 4.2 Distortions
• 4.2.1 Drifting
• 4.2.2 After Images
• 4.2.3 Tracers
• 4.2.4 Colour Shifting
• 4.2.5 Depth Perception Distortions
• 4.2.6 Diffraction
• 4.2.7 Scenery Slicing
• 4.2.8 Symmetrical Texture Repetition
• 4.3 Geometry
• 4.4 Hallucinatory States
• 4.4.1 Machinescapes
• 4.4.2 Transformations
• 4.4.3 Internal Hallucination
• 4.4.4 External Hallucination
• 4.5 Cognitive Effects
• 4.6 Auditory Effects
• 4.7 Transpersonal Effects
• 4.8 Combination Effects
5. FAQ (Frequently Asked Questions)
   
   

Novel Lysergamide

1-Cyclopropionyl-N-methyl-N-isopropyllysergamide, commonly known as 1cP-MiPLA, is a recently discovered psychedelic substance belonging to the lysergamide class. This compound is closely associated with MiPLA, and there is speculation that it may act as a prodrug for MiPLA, although current data and anecdotal reports are insufficient to support this hypothesis.

Emergence and Synthesis

1cP-MiPLA emerged in the research chemical scene around 2020 or 2021, with the initial synthesis attributed to either Skyler Ulrich or a chemist/group known as Gerstmann. It shares this space with other novel lysergamides like 1cP-AL-LAD, appearing on various research chemical markets.

User Experiences

User reports suggest that the effects of 1cP-MiPLA closely resemble those of MiPLA. While some anecdotal accounts hint at subtle differences, it's crucial to note that this does not definitively indicate whether 1cP-MiPLA is a true prodrug for MiPLA. Many reported effects appear to be identical or nearly identical.

Limited Pharmacological Understanding

Despite its popularity, there is minimal data available on the pharmacological properties, metabolism, and toxicity of 1cP-MiPLA. Users commonly characterize it as more recreational and less threatening compared to LSD. However, caution and adherence to harm reduction practices are strongly advised due to its high potency and hallucinogenic nature.

Chemical Structure

1cP-MiPLA, or 1-Cyclopropionyl-N-methyl-N-isopropyllysergamide, belongs to the lysergamide family as a semisynthetic alkaloid. Its chemical structure features a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). A Cyclopropionyl substituent is present at R1, and at carbon 8 of the quinoline, an N,N-diethyl carboxamide is bound.

1cP-MiPLA is a chiral compound with two stereocenters at R5 and R8. Known as (+)-D-1cP-MiPLA, it has an absolute configuration of (5R, 8R). The three other stereoisomers of 1cP-MiPLA are presumed to lack psychoactive properties.

Pharmacology of 1cP-MiPLA

Mechanism of Action

1cP-MiPLA is believed to act as a 5-HT2A partial agonist, with its psychedelic effects attributed to its efficacy at the 5-HT2A receptors. Despite this understanding, the precise role of these interactions and how they lead to the psychedelic experience remain subjects of ongoing scientific investigation.

Prodrug Potential

The 1-Cyclopropionyl substitution in 1cP-MiPLA suggests that it may function as a prodrug for MiPLA, similar to the relationship between 1cP-LSD and LSD. However, the limited data and absence of sufficient anecdotes make it challenging to conclusively establish this property for 1cP-MiPLA.

Comparison with LSD

1cP-MiPLA shares common traits with its parent compound LSD. In human subjects, it exhibits comparable or lower potency and a similar mechanism of action. Notably, the progression and duration of effects are condensed, resulting in a qualitatively less intense and more manageable experience, potentially due to more rapid catabolism. It is also observed to be less potent than LSD.

Dosage Information

• Threshold: 50 µg
• Light: 100 - 150 µg
• Common: 150 - 200 µg
• Strong: 200 - 250 µg
• Heavy: 300 µg and above

Subjective Effects

While 1cP-MiPLA's subjective effects largely overlap with those of MiPLA and to a lesser extent LSD, it is frequently reported to have a significantly shorter duration and be less uncomfortable in terms of negative physical side effects and general anxiety.

Disclaimer: The effects mentioned are based on the Subjective Effect Index (SEI), derived from open research literature and anecdotal user reports. It is essential to approach these effects with skepticism, as they may not occur predictably or reliably. Higher doses are more likely to induce the full spectrum of effects, with increased risk of adverse effects such as addiction, severe injury, or death.

Physical Effects of 1cP-MiPLA

Stimulation

Similar to LSD, 1cP-MiPLA is primarily characterized as a stimulating substance. This sets it apart from more commonly used psychedelics like psilocybin, which tend to induce sedation and relaxedness.

Spontaneous Bodily Sensations

The "body high" associated with 1cP-MiPLA is described as proportionally intense compared to its visual and cognitive effects. It manifests as a pleasurable, rapid-moving, sharp, and location-specific tingling sensation. While some users may experience it spontaneously at unpredictable points during the experience, for most, it remains consistently present, intensifying with the onset and reaching its peak during the climax. In comparison to LSD, the tingling sensations produced by 1cP-MiPLA are slightly less sharp but otherwise essentially indistinguishable.

Visual Effects of 1cP-MiPLA

Enhancements

1cP-MiPLA induces a range of visual enhancements, including:

• Visual Acuity Enhancement
• Colour Enhancement
• Pattern Recognition Enhancement

Distortions

1cP-MiPLA produces various distortions akin to LSD, including:

Drifting

Highly detailed yet cartoon-like, the drifting is slow, smooth, and resembles LSD visuals closely.

• After Images
• Tracers
• Colour Shifting
• Depth Perception Distortions
• Diffraction
• Scenery Slicing
• Symmetrical Texture Repetition

Geometry

The visual geometry evoked by 1cP-MiPLA is comparable to LSD, 2C-B, or 4-HO-MET. It is intricate, algorithmic, unstructured, brightly lit, colorful, cartoonish, organic, flat in shading, with soft edges. At higher doses, it reaches Level 8B visual geometry, more intense than Level 8A. Compared to LSD, 1cP-MiPLA's geometry tends to be slightly softer, warmer, and less intricate.

Hallucinatory States

1cP-MiPLA can induce low to high-level hallucinatory states, less consistently than some psychedelics but more likely compared to LSD. Effects include:

• Machinescapes
• Transformations
• Internal Hallucination

Consistent in dark environments at high doses, featuring lucid, interactive, and diverse content.

External Hallucination

Cognitive Effects

Various cognitive effects are reported, including:

Analysis Enhancement

Consistently enhancing analysis and outrospection.

• Conceptual Thinking
• Cognitive Euphoria
• Novelty Enhancement
• Immersion Enhancement
• Focus Enhancement

Exclusively on low or threshold dosages, less forced than stimulants.

• Motivation Enhancement
• Emotion Enhancement
• Increased Music Appreciation
• Increased Sense of Humor
• Laughter Fits
• Memory Suppression
• Ego Death
• Time Distortion
• Déjà Vu
• Delusion
• Thought Acceleration
• Thought Loops
• Wakefulness
• Auditory Effects
• Auditory experiences include:
• Auditory Distortion
• Auditory Enhancement
• Auditory Hallucination

Transpersonal Effects

Reports suggest weaker transpersonal effects compared to LSD and other psychedelics, including:

• Existential Self-Realization
• Unity and Interconnectedness

Combination Effects

1cP-MiPLA can interact with other substances:

Alcohol

Counteracts anxiety but can cause dehydration and fatigue. Pacing is advised.

Benzodiazepines

Effectively reduces the intensity of 1cP-MiPLA's effects through general brain activity suppression.

Cannabis

Intensifies effects; extreme caution is urged due to increased risk of negative psychological reactions.

Dissociatives

Enhances cognitive, visual, and hallucinatory effects, increasing the risk of confusion, delusions, and psychosis.

MDMA

Highly synergistic, mutually enhancing physical, cognitive, and visual effects. Caution required due to potential increased neurotoxicity.

Note: Users should approach substance combinations with caution, adjusting doses and taking breaks to mitigate potential risks.

Physical Euphoria

Physical euphoria on 1cP-MiPLA is not as consistent as with substances like stimulants or entactogens. It can manifest as physical discomfort without an apparent reason, presenting a variable aspect of the overall experience.

Changes in Felt Bodily Form

Often accompanied by a sense of warmth or unity, changes in felt bodily form occur during and up to the peak of the experience or directly afterward. Users may feel physically connected or conjoined with other objects, and this is generally reported as a comfortable and peaceful sensation.

Tactile Enhancement

Feelings of enhanced tactile sensations persist consistently at moderate levels throughout most 1cP-MiPLA trips, contributing to an overall heightened sensory experience.

Other Physical Effects

• Temperature Regulation Suppression
• Increased Bodily Temperature
• Nausea
• Stamina Enhancement (mild compared to traditional stimulants)
• Bodily Control Enhancement
• Appetite Suppression
• Difficulty Urinating
• Increased Blood Pressure
• Increased Heart Rate
• Increased Perspiration
• Muscle Contractions
• Muscle Spasms
• Increased Libido
• Excessive Yawning (less pronounced than with psilocybin and related compounds)
• Pupil Dilation
• Increased Salivation
• Seizure (potential risk, particularly in those genetically predisposed, under physically taxing conditions)

Note: The possibility of seizures is inferred from reports following LSD use, especially in individuals genetically predisposed, particularly when combined with physically demanding conditions such as dehydration, fatigue, or undernourishment.

FAQ (Frequently Asked Questions)

Q1: What is 1cP-MiPLA? 

A1: 1cP-MiPLA is a novel lysergamide, part of the psychedelic class, suspected to be a prodrug for MiPLA.

Q2: When did 1cP-MiPLA first appear?

 A2: It first appeared in the research chemical scene around 2020 or 2021, synthesized by Skyler Ulrich or the chemist/group Gerstmann.

Q3: How does 1cP-MiPLA compare to LSD? 

A3: 1cP-MiPLA shares traits with LSD but is reported to be less intense and has differences in visual geometry.

Q4: What are the recommended dosages for 1cP-MiPLA? 

A4: Threshold: 50 µg, Light: 100 - 150 µg, Common: 150 - 200 µg, Strong: 200 - 250 µg, Heavy: 300 µg and above.

Q5: Are there any potential risks associated with 1cP-MiPLA use?

 A5: Yes, potential risks include seizures, especially in those predisposed, and adverse effects like nausea and increased heart rate.

Q6: How does 1cP-MiPLA interact with other substances? 

A6: It interacts differently with alcohol, benzodiazepines, cannabis, dissociatives, and MDMA. Caution is advised for substance combinations.

Q7: Are the visual effects of 1cP-MiPLA similar to LSD? 

A7: Yes, the visual effects include enhancements, distortions, intricate visual geometry, and hallucinatory states similar to LSD but with some distinctions.

Q8: Can 1cP-MiPLA induce ego death? 

A8: Yes, ego death is listed among the cognitive effects of 1cP-MiPLA.

Q9: How should users approach the combination of 1cP-MiPLA with cannabis?

 A9: Extreme caution is advised due to a significant increase in the chances of negative psychological reactions. Users should start with a fraction of their usual cannabis dose.

Q10: Is there evidence of neurotoxicity when combining 1cP-MiPLA with MDMA? 

A10: Some evidence suggests that co-administration of LSD with MDMA increases neurotoxicity, and this may extend to 1cP-MiPLA. Caution is recommended, and lower doses are advised for combined use.